Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR21734] to VASP (phospho S239)
- Suitable for: WB, Dot blot, IP
- Reacts with: Human
Product nameAnti-VASP (phospho S239) antibody [EPR21734]
See all VASP primary antibodies
DescriptionRabbit monoclonal [EPR21734] to VASP (phospho S239)
Tested applicationsSuitable for: WB, Dot blot, IPmore details
Species reactivityReacts with: Human
Synthetic peptide within Human VASP aa 200-300 (phospho S239). The exact sequence is proprietary.
Database link: P50552
- WB: THP-1, untreated and treated with 10µM forskolin for 30 minutes, whole cell lysate. IP: THP-1 treated with 10uM forskolin for 30 minutes whole cell lysate.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol, 0.05% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab218619 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000. Detects a band of approximately 46 kDa (predicted molecular weight: 39 kDa).|
FunctionEna/VASP proteins are actin-associated proteins involved in a range of processes dependent on cytoskeleton remodeling and cell polarity such as axon guidance, lamellipodial and filopodial dynamics, platelet activation and cell migration. VASP promotes actin filament elongation. It protects the barbed end of growing actin filaments against capping and increases the rate of actin polymerization in the presence of capping protein. VASP stimulates actin filament elongation by promoting the transfer of profilin-bound actin monomers onto the barbed end of growing actin filaments. Plays a role in actin-based mobility of Listeria monocytogenes in host cells. Regulates actin dynamics in platelets and plays an important role in regulating platelet aggregation.
Tissue specificityHighly expressed in platelets.
Sequence similaritiesBelongs to the Ena/VASP family.
Contains 1 WH1 domain.
DomainThe EVH2 domain is comprised of 3 regions. Block A is a thymosin-like domain required for G-actin binding. The KLKR motif within this block is essential for the G-actin binding and for actin polymerization. Block B is required for F-actin binding and subcellular location, and Block C for tetramerization.
The WH1 domain mediates interaction with XIRP1.
modificationsMajor substrate for cAMP-dependent (PKA) and cGMP-dependent protein kinase (PKG) in platelets. The preferred site for PKA is Ser-157, the preferred site for PKG, Ser-239. In ADP-activated platelets, phosphorylation by PKA or PKG on Ser-157 leads to fibrinogen receptor inhibition. Phosphorylation on Thr-278 requires prior phosphorylation on Ser-157 and Ser-239. In response to phorbol ester (PMA) stimulation, phosphorylated by PKC/PRKCA. In response to thrombin, phosphorylated by both PKC and ROCK1. Phosphorylation at Thr-278 by AMPK does not require prior phosphorylation at Ser-157 or Ser-239. Phosphorylation modulates F-actin binding, actin filament elongation and platelet activation. Carbon monoxide (CO) promotes phosphorylation at Ser-157, while nitric oxide (NO) promotes phosphorylation at Ser-157, but also at Ser-239. Response to NO and CO is blunted in platelets from diabetic patients, and VASP is not phosphorylated efficiently at Ser-157 and Ser-239.
Cellular localizationCytoplasm. Cytoplasm > cytoskeleton. Cell junction > focal adhesion. Cell projection > lamellipodium membrane. Cell projection > filopodium membrane. Targeted to stress fibers and focal adhesions through interaction with a number of proteins including MRL family members. Localizes to the plasma membrane in protruding lamellipodia and filopodial tips. Stimulation by thrombin or PMA, also translocates VASP to focal adhesions. Localized along the sides of actin filaments throughout the peripheral cytoplasm under basal conditions.
- Information by UniProt
- Vasodilator stimulated phosphoprotein antibody
- Vasodilator-stimulated phosphoprotein antibody
- VASP antibody
- VASP_HUMAN antibody
All lanes : Anti-VASP (phospho S239) antibody [EPR21734] (ab218619) at 1/1000 dilution
Lane 1 : Untreated THP-1 (human monocytic leukemia cell line) whole cell lysate
Lane 2 : THP-1 treated with 10µM forskolin for 30 minutes, whole cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Predicted band size: 39 kDa
Observed band size: 46 kDa why is the actual band size different from the predicted?
Exposure time: 3 minutes
Blocking/Diluting buffer and concentration: 5% NFDM/TBST
This blot was developed using a higher sensitivity ECL substrate.
VASP (phospho S239) was immunoprecipitated from 0.35 mg THP-1 (human monocytic leukemia cell line) treated with 10µM forskolin for 30min whole cell lysate using ab218619 at 1/30 dilution. Western blot was performed on the immunoprecipitate using ab218619 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366) was used for detection at 1/1000 dilution.
Lane 1: THP-1 treated with 10µM forskolin for 30min whole cell lysate 10μg (input).
Lane 2: ab218619 IP in THP-1 treated with 10µM forskolin for 30min whole cell lysate.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab218619 in THP-1 treated with 10µM forskolin for 30min whole cell lysate.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 3 minutes.
Dot blot analysis of VASP (phospho S239) using ab218619 at 1/1000 dilution, followed byGoat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/100,000 dilution.
Lane 1: VASP (phospho S239) peptide
Lane 2: VASP non-phospho peptide.
Blocking/Diluting buffer and concentration: 5% NFDM/TBST.
Exposure time: 58 seconds.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab218619 has not yet been referenced specifically in any publications.